ijms-logo

Journal Browser

Journal Browser

Cardiovascular and Cerebrovascular Diseases: From Pathology to Therapeutic Perspectives

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 3532

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medical Physiology, Texas A&M University Health Science Center, Bryan, TX 77807, USA
Interests: vascular biology; cardiovascular pathophysiology; coronary ischemia; diabetic and hypertensive retinopathy; oxidative stress
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular and cerebrovascular diseases are diseases of the blood vessels in the heart and brain. They are common causes of premature death and disability in humans.

This Special Issue aims to collect high-quality research articles, comprehensive reviews, and novel communications reflecting fundamental and molecular research on all kinds of cardiovascular and cerebrovascular diseases. We encourage the submission of manuscripts that provide novel and mechanistic insights and papers that report significant advances in the field.

The topics of interest for this Special Issue include, but are not limited to, the following:

  • Aneurysms;
  • Aortic disease;
  • Cerebrovascular disease;
  • Congenital heart disease;
  • Coronary/cerebral artery disease;
  • Coronary/cerebral ischemia;
  • Coronary/cerebral thrombosis;
  • Deep vein thrombosis;
  • Genetic cardiovascular/cerebrovascular disease;
  • Heart attack;
  • Heart failure;
  • Heart muscle disease;
  • Heart valve disease;
  • Lymphatic pathophysiology;
  • Microvascular disorder;
  • Pericardial disease;
  • Peripheral vascular disease;
  • Rheumatic heart disease;
  • Stroke;
  • Transient ischemic attack;
  • (repetitive)Vascular remodeling/dysfunction/malformation.

We will focus our attention on fundamental cellular/molecular studies, but scientific articles that incorporate clinical data in addition to cellular/molecular studies will be equally considered.

Prof. Dr. Lih Kuo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • cerebrovascular diseases
  • cardio-neuro-vascular
  • molecular pathology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 626 KiB  
Review
Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk
by Oana-Viola Badulescu, Dragos Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum and Iris Bararu Bojan
Int. J. Mol. Sci. 2024, 25(14), 7845; https://doi.org/10.3390/ijms25147845 - 18 Jul 2024
Cited by 1 | Viewed by 1247
Abstract
Navigating through antithrombotic therapy in patients with both hemophilia and cardiovascular pathology presents a complex scenario with inherent challenges and opportunities. The presence of hemophilia, characterized by impaired blood clotting, adds a layer of complexity to the management of cardiovascular conditions requiring antiplatelet [...] Read more.
Navigating through antithrombotic therapy in patients with both hemophilia and cardiovascular pathology presents a complex scenario with inherent challenges and opportunities. The presence of hemophilia, characterized by impaired blood clotting, adds a layer of complexity to the management of cardiovascular conditions requiring antiplatelet therapy and anticoagulation. Striking a delicate balance between the necessity for antithrombotic treatment to prevent cardiovascular events and the heightened risk of severe bleeding in individuals with hemophilia demands a nuanced and carefully considered approach. The challenges revolve around identifying an optimal therapeutic strategy that effectively mitigates cardiovascular risks without exacerbating bleeding tendencies. In hemophilic patients with cardiovascular disease, the decision to use antiplatelet therapy requires careful consideration of the individual’s bleeding risk profile, considering factors such as the severity of hemophilia, history of bleeding episodes, and concurrent medications. The goal is to provide effective antithrombotic treatment while minimizing the potential for excessive bleeding complications. Conventional anticoagulants like warfarin pose difficulties due to their potential to increase the risk of bleeding. On the other hand, emerging options like novel direct oral anticoagulants (DOACs) present an opportunity, offering predictable pharmacokinetics and user-friendly administration. However, a comprehensive exploration of their safety and efficacy in hemophilic patients is imperative. Achieving the right equilibrium between preventing cardiovascular events and minimizing bleeding risk is pivotal in selecting the most effective therapeutic option for individuals with hemophilia and cardiovascular pathology. A multidisciplinary approach, integrating the expertise of hematologists and cardiologists, becomes essential to customize treatments and address the intricacies of this medical challenge. Full article
Show Figures

Figure 1

18 pages, 933 KiB  
Review
Comprehensive Management of Stroke: From Mechanisms to Therapeutic Approaches
by Ana Arnalich-Montiel, Alba Burgos-Santamaría, Laia Pazó-Sayós and Begoña Quintana-Villamandos
Int. J. Mol. Sci. 2024, 25(10), 5252; https://doi.org/10.3390/ijms25105252 - 11 May 2024
Cited by 2 | Viewed by 1585
Abstract
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are [...] Read more.
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are eligible for this time-sensitive treatment. Even though there is still significant room for improvement in the management of this group of patients, up until now there have been no alternative therapies approved for use in clinical practice. However, there is still hope, as clinical research with novel emerging therapies is now generating promising results. These drugs happen to stop or palliate some of the underlying molecular mechanisms involved in cerebral ischemia and secondary brain damage. The aim of this review is to provide a deep understanding of these mechanisms and the pathogenesis of AIS. Later, we will discuss the potential therapies that have already demonstrated, in preclinical or clinical studies, to improve the outcomes of patients with AIS. Full article
Show Figures

Figure 1

Back to TopTop